Semaglutide fails in phase II trial within fatty liver disease
Novo Nordisk joins a string of other companies in acknowledging that a fatty liver can be hard to treat. On Wednesday, the company reports that its NASH therapy has failed in a phase II study as a monotherapy against the disease.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Non-alcoholic fatty liver disease, also known as NASH, has proven itself to be somewhat of a headache for several companies trying to develop treatments for the disease, and Novo Nordisk might be the latest addition to the group.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
.jpg)
.jpg&w=384&q=75)
